Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2015

01-12-2015 | Breast Oncology

Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case–Control Study

Authors: Laura C. Collins, MD, Ninah Achacoso, MS, Reina Haque, PhD, MPH, Larissa Nekhlyudov, MD, Charles P. Quesenberry Jr., PhD, Stuart J. Schnitt, MD, Laurel A. Habel, PhD, Suzanne W. Fletcher, MD

Published in: Annals of Surgical Oncology | Special Issue 3/2015

Login to get access

Abstract

Background

Various patient, treatment, and pathologic factors have been associated with an increased risk of local recurrence (LR) following breast-conserving therapy (BCT) for ductal carcinoma in situ (DCIS). However, the strength and importance of individual factors has varied; whether combining factors improves prediction, particularly in community practice, is uncertain. In a large, population-based cohort of women with DCIS treated with BCT in three community-based practices, we assessed the validity of the Memorial Sloan-Kettering Cancer Center (MSKCC) DCIS nomogram, which combines clinical, pathologic, and treatment features to predict LR.

Methods

We reviewed slides of patients with unilateral DCIS treated with BCT. Regression methods were used to estimate risks of LR. The MSKCC DCIS nomogram was applied to the study population to compare the nomogram-predicted and observed LR at 5 and 10 years.

Results

The 495 patients in our study were grouped into quartiles and octiles to compare observed and nomogram-predicted LR. The 5-year absolute risk of recurrence for lowest and highest quartiles was 4.8 and 33.1 % (95 % CI 3.1–6.4 and 24.2–40.9, respectively; p < 0.0001). The overall correlation between 10-year nomogram-predicted recurrences and observed recurrences was 0.95. Compared with observed 10-year LR rates, the risk estimates provided by the nomogram showed good correlation, and reasonable discrimination with a c-statistic of 0.68.

Conclusions

The MSKCC DCIS nomogram provided good prediction of the 5- and 10-year LR when applied to a population of patients with DCIS treated with BCT in a community-based practice. This nomogram, therefore, is a useful treatment decision aid for patients with DCIS.
Literature
1.
go back to reference Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol. 2008;15(1):235–43.PubMedCrossRef Meijnen P, Oldenburg HS, Peterse JL, Bartelink H, Rutgers EJ. Clinical outcome after selective treatment of patients diagnosed with ductal carcinoma in situ of the breast. Ann Surg Oncol. 2008;15(1):235–43.PubMedCrossRef
2.
go back to reference Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.PubMedCrossRef Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–7.PubMedCrossRef
3.
go back to reference Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692–702.PubMedCrossRef Kerlikowske K, Molinaro A, Cha I, et al. Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003;95(22):1692–702.PubMedCrossRef
4.
go back to reference Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–46.PubMedCrossRef Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer. 2005;103(6):1137–46.PubMedCrossRef
5.
go back to reference Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19(8):2263–71.PubMed Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001;19(8):2263–71.PubMed
6.
go back to reference Solin LJ, McCormick B, Recht A, et al. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am. 1996;2(3):158.PubMed Solin LJ, McCormick B, Recht A, et al. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-conserving surgery and definitive breast irradiation. Cancer J Sci Am. 1996;2(3):158.PubMed
7.
go back to reference Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28(4):400–18.PubMedCrossRef Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28(4):400–18.PubMedCrossRef
8.
go back to reference Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.PubMedCrossRef Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353(9169):1993–2000.PubMedCrossRef
9.
go back to reference Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol. 2000;24(8):1058–67.PubMedCrossRef Goldstein NS, Kestin L, Vicini F. Intraductal carcinoma of the breast: pathologic features associated with local recurrence in patients treated with breast-conserving therapy. Am J Surg Pathol. 2000;24(8):1058–67.PubMedCrossRef
10.
go back to reference Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18(2):296–306.PubMed Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18(2):296–306.PubMed
11.
go back to reference Van Zee KJ, Liberman L, Samli B, et al. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86(9):1757–67.PubMedCrossRef Van Zee KJ, Liberman L, Samli B, et al. Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer. 1999;86(9):1757–67.PubMedCrossRef
12.
go back to reference Schnitt SJ. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr. 2010;2010(41):158–61.PubMedCrossRef Schnitt SJ. Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics. J Natl Cancer Inst Monogr. 2010;2010(41):158–61.PubMedCrossRef
13.
go back to reference Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.PubMedCrossRef Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol. 2010;28(23):3762–9.PubMedCrossRef
14.
go back to reference Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30(6):600–7.PubMedPubMedCentralCrossRef Yi M, Meric-Bernstam F, Kuerer HM, et al. Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol. 2012;30(6):600–7.PubMedPubMedCentralCrossRef
15.
go back to reference Sweldens C, Peeters S, van Limbergen E, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J. 2014;20(1):1–7.PubMedCrossRef Sweldens C, Peeters S, van Limbergen E, et al. Local relapse after breast-conserving therapy for ductal carcinoma in situ: a European single-center experience and external validation of the Memorial Sloan-Kettering Cancer Center DCIS nomogram. Cancer J. 2014;20(1):1–7.PubMedCrossRef
16.
go back to reference Wang F, Li H, Tan PH, et al. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for asian women with ductal carcinoma in situ of the breast. Clin Oncol. 2014;26(11):684–91.CrossRef Wang F, Li H, Tan PH, et al. Validation of a nomogram in the prediction of local recurrence risks after conserving surgery for asian women with ductal carcinoma in situ of the breast. Clin Oncol. 2014;26(11):684–91.CrossRef
17.
go back to reference Habel LA, Achacoso NS, Haque R, et al. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009;11(6):R85.PubMedPubMedCentralCrossRef Habel LA, Achacoso NS, Haque R, et al. Declining recurrence among ductal carcinoma in situ patients treated with breast-conserving surgery in the community setting. Breast Cancer Res. 2009;11(6):R85.PubMedPubMedCentralCrossRef
18.
go back to reference Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139(2):453–60.PubMedPubMedCentralCrossRef Collins LC, Achacoso N, Haque R, et al. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast Cancer Res Treat. 2013;139(2):453–60.PubMedPubMedCentralCrossRef
19.
go back to reference Langholz B, Borgan O. Estimation of absolute risk from nested case-control data. Biometrics. 1997;53(2):767–74.PubMedCrossRef Langholz B, Borgan O. Estimation of absolute risk from nested case-control data. Biometrics. 1997;53(2):767–74.PubMedCrossRef
20.
go back to reference Brentnall AR, Cuzick J, Field JR, Duffy SW. A concordance index for matched case–control studies with applications in cancer risk. Stat Med. 2014. doi:10.1002/sim.6335.PubMed Brentnall AR, Cuzick J, Field JR, Duffy SW. A concordance index for matched case–control studies with applications in cancer risk. Stat Med. 2014. doi:10.​1002/​sim.​6335.PubMed
21.
go back to reference Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71.PubMedPubMedCentralCrossRef Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26(25):4063–71.PubMedPubMedCentralCrossRef
22.
go back to reference Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.PubMedCrossRef Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93(5):358–66.PubMedCrossRef
23.
go back to reference Van Zee KJ, Patil S. Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ. J Clin Oncol. 2012;30(25):3143–4; author reply 3144–5.PubMedCrossRef Van Zee KJ, Patil S. Validation of a nomogram for predicting risk of local recurrence for ductal carcinoma in situ. J Clin Oncol. 2012;30(25):3143–4; author reply 3144–5.PubMedCrossRef
25.
go back to reference Elmore JG, Fletcher SW. The risk of cancer risk prediction: “What is my risk of getting breast cancer”? J Natl Cancer Inst. 2006;98(23):1673–5.PubMedCrossRef Elmore JG, Fletcher SW. The risk of cancer risk prediction: “What is my risk of getting breast cancer”? J Natl Cancer Inst. 2006;98(23):1673–5.PubMedCrossRef
26.
go back to reference Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.PubMedPubMedCentralCrossRef Solin LJ, Gray R, Baehner FL, et al. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst. 2013;105(10):701–10.PubMedPubMedCentralCrossRef
27.
go back to reference Rakovitch E, Nofech-Mozes S, Hanna W, et al. Abstract S5-04: A large prospectively-designed study of the DCIS score: predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. Cancer Res. 2015. doi:10.1158/1538-7445.SABCS14-S5-04. Rakovitch E, Nofech-Mozes S, Hanna W, et al. Abstract S5-04: A large prospectively-designed study of the DCIS score: predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation. Cancer Res. 2015. doi:10.​1158/​1538-7445.​SABCS14-S5-04.
28.
go back to reference Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–37.PubMedPubMedCentralCrossRef Kerlikowske K, Molinaro AM, Gauthier ML, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102(9):627–37.PubMedPubMedCentralCrossRef
Metadata
Title
Risk Prediction for Local Breast Cancer Recurrence Among Women with DCIS Treated in a Community Practice: A Nested, Case–Control Study
Authors
Laura C. Collins, MD
Ninah Achacoso, MS
Reina Haque, PhD, MPH
Larissa Nekhlyudov, MD
Charles P. Quesenberry Jr., PhD
Stuart J. Schnitt, MD
Laurel A. Habel, PhD
Suzanne W. Fletcher, MD
Publication date
01-12-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue Special Issue 3/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-015-4641-x

Other articles of this Special Issue 3/2015

Annals of Surgical Oncology 3/2015 Go to the issue